Clinical Trial Update: Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT) [Phase 2]

View source ↗

Summary

This update reports that the Phase 2 trial of ixabepilone in HER-2 negative metastatic breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ixempra (ixabepilone)

Snippet

Sponsor: Hellenic Cooperative Oncology Group | Conditions: Metastatic Breast Cancer | Phase 2 | Status: TERMINATED